Wharton's Jelly Stem Cells

Cord blood contains hematopoietic (blood-forming) stem cells, while Wharton's Jelly contains mesenchymal stem cells (MSCs). MSCs from Wharton's Jelly have stronger immunomodulatory and anti-inflammatory properties, which are more relevant to addressing the biological factors associated with autism, such as neuroinflammation and immune dysregulation.

Wharton's Jelly MSCs are isolated from neonatal connective tissue rather than adult bone marrow or fat. They have longer telomeres, higher proliferative capacity, stronger paracrine signaling, and greater anti-inflammatory potency per cell than adult-derived MSCs. For children with autism — where the biological targets are inflammation, immune modulation, and neurological signaling — these qualities make them an especially relevant cell source.

Wharton's Jelly MSCs have an extensively documented safety profile in clinical research. They are immunologically privileged (low HLA expression) and have low tumorigenic risk in published data. At Autism Stem Care, every donor undergoes comprehensive infectious disease and genetic screening, and every batch is tested for sterility, viability, and identity before release. Safety also depends on careful patient selection — not every child is a candidate, and a medical review is mandatory.

They are collected from umbilical cord tissue donated after healthy, full-term births with full informed consent from the mother. The umbilical cord would otherwise be discarded as medical waste. There is no risk or pain to the mother or baby, and no embryonic or fetal tissue is involved at any stage.

The two most common routes are intravenous (IV) infusion for systemic immunomodulatory effect and intrathecal administration for more direct access to the central nervous system. The route, dose, and number of sessions are decided individually as part of the personalized treatment plan, based on the child's clinical profile and the goals of the protocol.

Within the autism spectrum, families most often ask about Wharton's Jelly MSCs in the context of neuroinflammation, immune dysregulation, gut–brain axis disturbance, oxidative stress, and challenges with attention, sleep, sensory regulation, or social engagement. These cells are not a cure — they may be considered as one component of a broader, individualized regenerative protocol.

Protocols vary by case. Many international families travel for a structured multi-day course that may include several MSC infusions combined with adjunctive therapies, and a follow-up review is typically scheduled at 3 and 6 months. The specific number of sessions is always determined after the medical review — we do not sell standardized 'packages' detached from clinical reasoning.

MSCs themselves are large cells and do not freely cross an intact blood–brain barrier. However, their therapeutic effects are believed to be primarily paracrine — meaning they release exosomes, cytokines, and growth factors that can influence the central nervous system indirectly. Intrathecal administration is sometimes considered when more direct CNS exposure is clinically appropriate.

Reported observations vary widely between children and are never guaranteed. Families most often describe gradual changes in sleep quality, gut comfort, attention, eye contact, sensory tolerance, and engagement during therapies. Some children show no significant change. Honest framing of expectations is a core part of our consultation and follow-up process.

Cells are processed in laboratories operating to GMP-aligned standards. Each batch is characterized for viability, surface marker expression (CD73, CD90, CD105 positive; CD34, CD45 negative), sterility, mycoplasma, and endotoxin levels. Documentation is reviewed before any product is approved for clinical use. Parents are welcome to ask for an explanation of the quality dossier during consultation.

Yes. Combined MSC + exosome protocols are one of the most commonly discussed approaches in autism-focused regenerative medicine. The rationale is that MSCs provide sustained living-cell signaling while exosomes deliver concentrated, ready-to-act extracellular vesicle cargo. Whether combination therapy is appropriate is decided individually as part of the personalized plan.

MSC-based regenerative therapy for autism is not approved as a standard treatment by agencies such as the FDA or EMA. It is an investigational/regenerative medicine option, and outcomes are not guaranteed. At Autism Stem Care it is offered within a regulated Turkish medical framework with full clinical oversight, but families should always understand the investigational nature before proceeding.